Skip to contentT
Travere Therapeutics, Inc.
T
TVTXTravere Therapeutics, Inc. Q3 2023 · 10-Q
Revenue$37.10M$37.10M+32.1% vs Q3 2022 Net Income$150.74M$150.74MN/M vs Q3 2022 EPS Diluted$1.97$1.97N/M vs Q3 2022 Operating Income-$92,585,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Travere Therapeutics, Inc. · CIK 1438533 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$59,144,000N/M Margins · derivedOperating margin-249.6%+44.6 pt vs Q3 2022
Net margin406.3%+654.5 pt vs Q3 2022
ended Sep 30, 2023 · filed Nov 7, 2023 · 38 d after period end